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ABSTRACT 
Background: Rupatadine is a histamine receptor type 1 antagonist that has 
been used to treat allergic rhinitis and urticaria. 
Objective: The aim of this study was to compare the effect of 2 rupatadine 
tablet formulations on the inhibition of histamine-induced wheal-and-flare cutane- 
ous responses. 
Methods: In this single-blind, single oral dose, crossover study, healthy male 
volunteers were randomized to receive 10 mg of either a rupatadine reference 
or test formulation after an overnight fast. After a 10-day washout period, the 
subjects were crossed over to receive the other formulation. Subjects were 
asked to sit with their arm resting on the table while histamine was injected 
intradermally. The skin prick test was performed on the upper half of the 
volunteers' forearms before administration and at 1, 2, 4, 6, 12, and 24 hours 
after study drug administration. Fifteen minutes after each skin prick test, the 
wheal-and-flare sponses were visualized under a bright lamp. AUC0_24 was 
the primary end point. The 90% CI of least squares mean ratio (%) of the 
test:reference formulations for maximum inhibition of histamine-induced wheal- 
and-flare response (Imax%), Tmax, AUCo_24 mm2/h, and AUC0_24 %/hr were ex- 
pected to be within 80% to 125% of untransformed data and 80% to 120% of 
log-transformed data for the 2 formulations to be considered pharmacodynami- 
cally equivalent. Subjects were monitored for any spontaneously reported 
adverse event (AE) throughout the study. In addition, they were specifically 
asked about the occurrence of any AEs on a checklist (ie, drowsiness, dizziness, 
dryness of mouth, itching sensation, headache, nausea) throughout the study. 
Results: Of the 15 subjects assessed for inclusion, 12 healthy male volun- 
teers (mean [SD] age, 30 [5] years; height, 162 [6] cm; weight, 58 [6] kg) participated 
in the study. Administration of reference and test formulations of rupatadine 
significantly inhibited the histamine-induced cutaneous responses in all sub- 
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jects (P < 0.001). Wheal Imax~ with the reference and test formulations was 
67.97% (11.57%) and 66.76% (9.40%), respectively. Flare Imax% was 59.06% 
(11.95%) and 56.92% (16.31%), respectively. None of the subjects withdrew from 
the study due to AEs. Both formulations were well tolerated except for an itch- 
ing sensation on injection of histamine in all patients; no subject complained of 
any adverse drug reaction. 
Conclusion: In this small study of healthy adult males, the test formulation 
of the rupatadine tablet was found to be pharmacodynamically equivalent to 
the reference formulation, as measured by inhibition of histamine-induced 
cutaneous wheal-and-flare sponses. (Curr Ther Res Clin Exp. 2007;68:400-408) 
Copyright © 2007 Excerpta Medica, Inc. 
Key words: rupatadine, healthy subjects, pharmacodynamic equivalence, 
histamine-induced cutaneous response. 
INTRODUCTION 
Rupatadine is a histamine receptor type 1 antagonist that has been used to 
manage allergic inflammatory conditions uch as urticaria and seasonal and 
perennial rhinitis. 1Rupatadine has a rapid onset of action (<0.75 hours after 
ingestion), and its long-lasting effect (>24 hours) permits once-daily administra- 
tion. At the recommended dose of 10 mg, rupatadine has been found to be free 
of sedative ffects. 
Studies 2,3 have suggested that histamine plays a pivotal role in the pathophysi- 
ology of urticaria. Histamine is stored primarily in skin mast cells and, when 
released, leads to parasympathetic nerve stimulation and increased vascular 
permeability. 4,5This, in turn, results in the formation of itchy, slowly expanding, 
erythematous wheals. 
Grant et al 6 measured the wheal-and-flare sponse to the injection of hista- 
mine after the oral administration of 6 antihistamines compared with placebo. 
Most antihistamines have been studied using this model, which allows for 
objective assessment of the effectiveness of these drugs. Papule and erythema 
inhibition tests have suggested that the majority of antihistamines xert an 
effect on this histamine-mediated skin reaction within 1 to 3 hours after oral 
administration. 6,7 
The aim of this study was to compare the effect of a test rupatadine formula- 
tion (Hetero Drugs Ltd., Hyderabad, India) with that of a reference formulation 
(Biosintetica Laboratories Ltd., Guarulhos, Brazil) in healthy male adult volun- 
teers under fasting conditions using the pharmacodynamic measure of inhibi- 
tion of histamine-induced wheal-and-flare cutaneous responses. 
SUBJECTS AND METHODS 
All volunteers provided written informed consent before entering the study, 
which was approved by the institutional ethics committee of Nizam's Institute of 
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Medical Sciences (Hyderabad, India). The study was conducted under the principles 
of the Declaration of Helsinki 8and the Guideline for Good Clinical Practice. 9 
Adult men were eligible for the study if they were within 15% of average height 
and weight based on the guidelines of the Life Insurance Corporation, Mumbai, 
India. In addition, they were to be healthy (as indicated by medical history and 
physical examination); to have a normal electrocardiogram and clinically accept- 
able blood and urine biochemistry, hematology, and serology laboratory find- 
ings, including HIV and hepatitis B surface antigen tests; and to have a positive 
histamine-induced cutaneous response (wheal diameter >8 mm). 
Exclusion criteria included having taken a prescr ibed or investigational drug 
within 4 weeks of the study or having a history of smoking or alcohol abuse, 
skin disease, or any allergic condition. 
This was a balanced, randomized, single-blind, single oral dose, crossover 
study. After the screening visit, each eligible volunteer was assigned using a 
random number table to receive a 10-mg tablet of either the rupatadine test or 
reference formulation. 
All subjects were admitted to the clinical research ward of Nizam's Institute 
of Medical Sciences the evening before the day of study drug administra- 
tion and remained there until 24 hours after administration. After a 10-hour 
overnight fast, the drugs were administered by a pharmacist  with 240 mL of 
drinking water. Subjects were administered the drugs while seated, and they 
remained seated for 2 hours. They were then allowed to engage in normal 
physical activity but were told to avoid any severe physical exertion during the 
24-hour study period. A 10-day washout period was allowed before the subjects 
were crossed over to receive the other drug. The 2 formulations were similar in 
color and taste but not identical in appearance or size. 
Histamine-Induced Wheal-and-Flare Skin Prick Test 
Skin pricks were per formed on the upper  half of each volunteer 's  forearm 
before administrat ion and at 1, 2, 4, 6, 12, and 24 hours  after administrat ion.  
A 100-mg/mL droplet  of h istamine solut ion was placed on an untested site 
and administered into the skin by piercing the superf icial  skin with a steri le 
lancet. The droplet  was gently wiped off after a minute and the wheal-and- 
flare react ion was visual ized under  a bright lamp after 15 minutes. The 
areas of wheal and flare were outl ined with a th in-t ipped marker and t raced 
onto acetate sheets  to make permanent  records,  which were subsequent ly  
used to measure  (in mm 2) the areas of wheal and flare. 1° Treatment  was 
administered by a pharmac is t  not associated with the study; the physic ian 
and the staff per forming the wheal-and-f lare test were bl inded to the treat- 
ment schedule.  
A standard breakfast, lunch, and dinner were served to all subjects at 3, 6, 
and 12 hours, respectively, after drug administration. Subjects were not permit- 
ted to smoke or consume alcohol or caffeinated beverages from 12 hours before 
administration until the end of the study (24 hours after administration). Vital 
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signs (ie, heart rate, blood pressure, respiratory rate, and temperature) were 
recorded before drug administration and before each histamine challenge. The 
intensity of the itching sensation to histamine injection, degree of drowsiness, 
and dryness of mouth were also recorded using a 100-mm visual analogue scale 
(0 = none to 100 = worst possible). 
Subjects were monitored for any spontaneously reported adverse vent (AE) 
throughout the study. In addition, they were specifically asked about the occur- 
rence of any AEs on a checklist (ie, drowsiness dizziness, dryness of mouth, 
itch sensation, headache, nausea) throughout he study. Serious AEs were 
defined as any medical emergency, disability, prolongation of hospital stay, or 
any unexpected AE. 
Blood samples were not drawn to measure serum rupatadine concentration. 
Pharmacodynamic Parameters 
To assess the equivalence of the 2 rupatadine formulations, the follow- 
ing pharmacodynamic parameters were calculated for each subject: (1) maxi- 
mum inhibition of the histamine-induced wheal-and-flare responses (Imax~) 
compared with baseline; (2) Tm~  of inhibition of the wheal-and-flare re- 
sponses (if Tm~  occurred at >1 point, the first occurrence was used); and 
(3) AUCo_24 for the wheal-and-flare responses (calculated using the linear 
trapezoidal method). 
Statistical Analysis 
Sample size was estimated using a power calculation based on other stud- 
ies. 11 It was estimated that after treatment with 2 drugs at least 12 subjects 
would be required to detect a significant difference of 20% in AUCo_24 between 
the 2 formulations at the 90% power level with an c¢ error of 5%. Data for the 
histamine-induced wheal-and-flare sponses, percentage inhibition compared 
with baseline, and their mean (SD) values are provided for all the subjects 
that completed the study. 
Analysis of variance (ANOVA) was performed (c¢ = 0.05) on untransformed 
and log-transformed parameters for Imax~ Tmax, and AUC0_24. ANOVA included 
sequence, subject-within-sequence, p riod, and treatment as factors. Each 
analysis also included calculation of the least square mean (LSM), difference 
between means, and SD or SE. 
CIs consisted of 2 one-sided tests for bioequivalence, 90% CIs for the differ- 
ence between treatments. LSMs were calculated for untransformed and log- 
transformed Im~ Tm~, and AUC0_24. 
The 90% CIs of the LSM ratio (%) of the test:reference formulations for peak 
activity Im~, Tm~, AUCo_24 mm2/hr, and AUC0_24 %/hr should have been within 
80% to 125% of untransformed data and 80% to 120% for log-transformed data 
for the 2 formulations to be considered pharmacodynamically equivalent. 
Power (the probability of detecting a 20% difference relative to the reference 
treatment, and LSM at the 5% significance l vel using a t test under the null hypoth- 
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esis of 0 difference) was calculated for untransformed and log-transformed 
Im~ Tm~, and AUC0_24. 
RESULTS 
Of the 15 subjects assessed for inclusion, 12 healthy male volunteers (mean 
[SD] age, 30 [5] years [range, 22-38 years]; height, 162 [6] cm; weight, 58 [6] kg) 
participated in the study. All subjects completed both periods of the study. 
Fifteen minutes after the skin prick test using a 100-mg/mL droplet of hista- 
mine solution, a significant wheal-and-flare cutaneous response was produced 
in all subjects. Administration of reference and test formulations of rupatadine 
significantly inhibited the histamine-induced cutaneous response in all the 
subjects (P < 0.001). 
Wheal-and-flare areas were similar before treatment with both formulations. 
The inhibition profiles of histamine-induced wheal-and-flare sponses for the 
2 formulations were not significantly different. The mean (SD) maximum inhibi- 
tion of histamine-induced wheal response (IWmax~) with the reference and test 
formulation was 67.97% (11.57%) and 66.76% (9.40%), respectively. Maximum 
inhibition of histamine-induced flare response (Ifmax~) was 59.06% (11.95%) and 
56.92% (16.31%), respectively (Table). 
Inhibition of wheal-and-flare areas was apparent and pronounced by 
2 hours after administration. Tm~  for the wheal and the flare responses did 
not differ significantly for the 2 rupatadine formulations. With the reference 
formulation, mean Tm~  for the wheal response and the flare response was 
5.00 (1.35) hours and 5.00 (1.04) hours, respectively. With the test formula- 
tion, these values were 4.67 (1.30) hours and 4.83 (1.34) hours, respectively 
(Table). 
The mean AUC0_24 for the wheal response was 1221.5 (227.6) mm2/h and 
1231.4 (125.6) mm2/h with the reference and test formulations, respectively; the 
difference was not significant (Figure 1). The AUC0_24 percentage inhibition of 
Table. Mean (SD) maximum measured inhibition of histamine-induced response 
(ImaxO/o), Tmax, and AUCo_24 for reference and test rupatadine formulations in 
healthy male volunteers (N = 12).* All data are mean (SD). 
Formulation Imax% Tmax, h AUC0_24 , %/h 
Reference 
Wheal area 67.97 (11.57) 5.00 (1.35) 1156.3 (256.6) 
Flare area 59.06 (11.95) 5.00 (1.04) 938.3 (386.2) 
Test 
Wheal area 66.76 (9.40) 4.67 (1.30) 1055.0 (282.2) 
Flare area 56.92 (16.31) 4.83 (1.34) 834.7 (361.5) 
*There were no significant between-group differences. 
404 
P. Usharani et al. 
120 - 
= Reference 
Test 
E 
E 
,,¢ 
e-  
e-  
90- 
60- 
30- 
0 I I I I I 
4 8 12 16 20 24 
Time (h) 
Figure 1. The percentage inhibition of histamine-induced cutaneous wheal response 
with the reference and test rupatadine formulations in healthy adult 
volunteers (N -- 12). 
the histamine-induced wheal response was also similar for the 2 formulations 
(1156.3% [256.5%]/h vs 1055.0% [282.2%]/h) (Table). 
The mean AUCo_24 for the flare response was not significantly different 
between the reference and the test formulations (12721.7 [2905.6] mm2/h vs 
13414.2 [2352.5] mm2/h) (Figure 2). The AUC0_24 percentage inhibition of the 
histamine-induced flare response was also similar for the 2 formulations 
(938.3% [386.2%]/h vs 834.7% [361.5%]/h) (Table). 
For IWmax~, the LSM ratio of the test:reference formulation for untransformed 
and log-transformed data was 96.4% (90% CI, 72.3-128.3) and 98.2% (90% CI, 
91.1-105.5), respectively. For Ifmax~, the LSM ratio of the test:reference formula- 
tion for untransformed and log-transformed data was 100.8% (90% CI, 92.9%- 
115.3%) and 100.3% (90% CI, 86.9%-124.8%). 
There was no significant difference in the AUC0_24 of percentage inhibition 
of histamine-induced flare response obtained with the reference and test for- 
mulations in the 24-hour study period (938.3% [386.2%]/h vs 834.7% [361.5%]/h, 
respectively). 
As the ratios of the untransformed and log-transformed data were between 
80% and 125%, the test rupatadine tablet was considered to be equivalent to the 
reference rupatadine tablet. 
All subjects completed both periods of the study. Both treatments were well 
tolerated. None of the subjects complained of drowsiness or dryness of the 
mouth. None of the subjects had any serious local or systemic AEs. Other than 
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Figure 2. The percentage inhibit ion of histamine-induced cutaneous flare response 
with  the reference and test rupatadine formulations in healthy adult 
volunteers (N = 12). 
reports of an itching sensation on injection of histamine in all patients, no AEs 
were reported by any subject. 
DISCUSSION 
We found that treatment with 10 mg of the test rupatadine formulation was 
associated with a marked inhibition of histamine-induced wheal-and-flare 
response in healthy adults that was comparable to the response with the refer- 
ence rupatadine formulation. Both formulations were comparable in activity 
and demonstrated apparent inhibition of the wheal-and-flare response, reach- 
ing maximal activity with both formulations at 5 hours. We also found that the 
time course of activity of the 2 formulations was comparable. 
A recent review 7 noted that experimental  models have been used to study 
the pharmacodynamics  of antihistamine activity on target organs. One such 
model, which measures the degree of inhibition of wheal and erythema forma- 
tion induced by intradural histamine injection after oral antihistamine admin- 
istration, allows for objective assessment of the degree of antihistaminic effect. 
The authors observed that most antihistamines have been studied using this 
model and routinely produced significant inhibition of wheal and erythema 
formation versus placebo. Using a similar model, we found that both rupata- 
dine formulations produced similar inhibition of cutaneous response over the 
24-hour study period. 
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We found peak activity by 5 hours after drug administration, which is in 
accordance with the study by del Cuvillo et al, 7 who found that the maximum 
effect on wheal and erythema formation was reached 5 to 8 hours after oral 
administration, while Cma X was reached much earlier. 
Using papule and ery thema testing, del Cuvillo et al repor ted  that t ime 
to action with rupatadine was 2 hours. These findings are similar to our 
findings in which inhibit ion of wheal-and-f lare areas was apparent  and pro- 
nounced by 2 hours  after administrat ion,  reaching Tma X at 5.00 (1.35) hours  
and 5.00 (1.04) hours ,  respect ive ly ,  with the re ference  formulat ion and 
4.67 (1.30) hours  and 4.83 (1.34) hours,  respect ively,  with the test formula- 
tion. Inhibition pers isted throughout  the 24-hour s tudy period. 
Our study had several imitations. In this small study we included 12 healthy 
subjects under control led conditions; trials with more subjects need to be con- 
ducted. Furthermore, we did not use software to calculate the wheal-and-flare 
cutaneous response. More sophist icated objective techniques that quantify 
blood flow to assess the wheal and flare response may be more helpful. 
CONCLUSION 
In this small study of healthy adult males, the test formulation of the rupatadine 
tablet was found to be pharmacodynamically equivalent to the reference tablet, as 
measured by inhibition of histamine-induced cutaneous wheal-and-flare sponses. 
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